drugset / Trial / NCT00387010

Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain

NCT00387010

Phase 3 Terminated 218 enrolled Cephalon
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal tablets on the anxiety symptoms commonly associated with chronic pain in patients with breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate patient functioning, and to determine any influences on the successful dose achieved.

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 100 ug Other
Subject Fentanyl Other / unclassified 200 ug Other
Subject Fentanyl Other / unclassified 400 ug Other
Subject Fentanyl Other / unclassified 600 ug Other
Subject Fentanyl Other / unclassified 800 ug Other

Indications